The Clinicopathological Features and Genetic Mutations in Gastric Cancer Patients According to EMAST and MSI Status

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Mar 4

PMID 32120855

Citations 7

Authors

Wen-Liang Fang

Ming-Huang Chen

Kuo-Hung Huang

Shih-Ching Chang

Chien-Hsing Lin

Yee Chao

Su-Shun Lo

Anna Fen-Yau Li

Chew-Wun Wu

Yi-Ming Shyr

Affiliations

Soon will be listed here.

Abstract

There has been no report regarding the clinicopathological features and genetic mutations regarding elevated microsatellite alterations at selected tetranucleotide repeats (EMAST) in gastric cancer (GC). The correlation among EMAST status, microsatellite instability (MSI) status, mutations of common GC-related genes and 16 DNA repair-associated genes, and the clinicopathological features were analyzed. Among the 360 GC patients enrolled, there were 76 (21.1%) with EMAST+ tumors and 284 with EMAST- tumors, and 59 (16.4%) were MSI-high (MSI-H) tumors, and 301 were microsatellite stable (MSS) tumors. Patients with EMAST+ tumors exhibited an earlier pathological T category and had more genetic mutations in the / pathway, and DNA repair-associated genes than those with EMAST- tumors. Patients with MSI-H tumors have more genetic mutations in the / pathway and DNA repair-associated genes than those with MSS tumors. In the subgroup analysis for MSI-H GC, EMAST+ tumors were associated with earlier pathological T and N categories, earlier TNM stages, higher frequency of DNA-repair-associated genetic mutations, and a better survival rate than EMAST- tumors. / pathway mutations may play an important role in EMAST+ and/or MSI-H GC. EMAST+/MSI-H tumors seem to represent a different subtype of gastric cancer from EMAST-/MSI-H tumors.

Citing Articles

Single-cell RNA sequencing to map tumor heterogeneity in gastric carcinogenesis paving roads to individualized therapy.

Xu J, Yu B, Wang F, Yang J Cancer Immunol Immunother. 2024; 73(11):233.

PMID: 39271545 PMC: 11399521. DOI: 10.1007/s00262-024-03820-4.

Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair.

Ooki A, Osumi H, Yoshino K, Yamaguchi K Gastric Cancer. 2024; 27(5):907-931.

PMID: 38922524 PMC: 11335850. DOI: 10.1007/s10120-024-01523-4.

Current and Future Biomarkers in Esophagogastric Adenocarcinoma.

Sappenfield R, Mehlhaff E, Miller D, Ebben J, Uboha N J Gastrointest Cancer. 2024; 55(2):549-558.

PMID: 38280174 DOI: 10.1007/s12029-023-01007-1.

EMAST Type of Microsatellite Instability-A Distinct Entity or Blurred Overlap between Stable and MSI Tumors.

Derfi K, Salar A, Cacev T, Kapitanovic S Genes (Basel). 2023; 14(7).

PMID: 37510378 PMC: 10380056. DOI: 10.3390/genes14071474.

Esophagogastric Cancers: Integrating Immunotherapy Therapy Into Current Practice.

Patel M, Kratz J, Lubner S, Loconte N, Uboha N J Clin Oncol. 2022; 40(24):2751-2762.

PMID: 35839430 PMC: 10476757. DOI: 10.1200/JCO.21.02500.

References

Benatti P, Gafa R, Barana D, Marino M, Scarselli A, Pedroni M . Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res. 2005; 11(23):8332-40. DOI: 10.1158/1078-0432.CCR-05-1030. View

Chen C, Zhang F, Zhou N, Gu Y, Zhang Y, He Y . Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis. Oncoimmunology. 2019; 8(5):e1581547. PMC: 6492970. DOI: 10.1080/2162402X.2019.1581547. View

Fang W, Huang K, Chang S, Lin C, Chen M, Chao Y . Comparison of the Clinicopathological Characteristics and Genetic Alterations Between Patients with Gastric Cancer with or Without Infection. Oncologist. 2019; 24(9):e845-e853. PMC: 6738298. DOI: 10.1634/theoncologist.2018-0742. View

Haugen A, Goel A, Yamada K, Marra G, Nguyen T, Nagasaka T . Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res. 2008; 68(20):8465-72. PMC: 2678948. DOI: 10.1158/0008-5472.CAN-08-0002. View

Lee H, Park K, Kim D, Lhn M, Kim W, Seo A . Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features. Curr Mol Med. 2016; 16(9):829-839. DOI: 10.2174/1566524016666161124103020. View

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Fang W, Huang K, Lan Y, Lin C, Chang S, Chen M . Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers. Oncotarget. 2015; 7(5):6201-20. PMC: 4868750. DOI: 10.18632/oncotarget.6641. View

Overman M, McDermott R, Leach J, Lonardi S, Lenz H, Morse M . Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017; 18(9):1182-1191. PMC: 6207072. DOI: 10.1016/S1470-2045(17)30422-9. View

Xu H, Feng Y, Jia Z, Yang J, Lu X, Li J . AXIN1 protects against testicular germ cell tumors via the PI3K/AKT/mTOR signaling pathway. Oncol Lett. 2017; 14(1):981-986. PMC: 5494680. DOI: 10.3892/ol.2017.6214. View

10.

Devaraj B, Lee A, Cabrera B, Miyai K, Luo L, Ramamoorthy S . Relationship of EMAST and microsatellite instability among patients with rectal cancer. J Gastrointest Surg. 2010; 14(10):1521-8. PMC: 2943582. DOI: 10.1007/s11605-010-1340-6. View

11.

Watson M, Berg M, Soreide K . Prevalence and implications of elevated microsatellite alterations at selected tetranucleotides in cancer. Br J Cancer. 2014; 111(5):823-7. PMC: 4150258. DOI: 10.1038/bjc.2014.167. View

12.

Fang W, Chang S, Lan Y, Huang K, Chen J, Lo S . Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J Surg. 2012; 36(9):2131-8. DOI: 10.1007/s00268-012-1652-7. View

13.

Mori T, Hamaya Y, Uotani T, Yamade M, Iwaizumi M, Furuta T . Prevalence of elevated microsatellite alterations at selected tetranucleotide repeats in pancreatic ductal adenocarcinoma. PLoS One. 2018; 13(12):e0208557. PMC: 6285458. DOI: 10.1371/journal.pone.0208557. View

14.

Kucherlapati M, Esfahani S, Habibollahi P, Wang J, Still E, Bronson R . Genotype directed therapy in murine mismatch repair deficient tumors. PLoS One. 2013; 8(7):e68817. PMC: 3720855. DOI: 10.1371/journal.pone.0068817. View

15.

Watson M, Lea D, Rewcastle E, Hagland H, Soreide K . Elevated microsatellite alterations at selected tetranucleotides in early-stage colorectal cancers with and without high-frequency microsatellite instability: same, same but different?. Cancer Med. 2016; 5(7):1580-7. PMC: 4944885. DOI: 10.1002/cam4.709. View

16.

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

17.

Venderbosch S, Vliet S, de Haan A, Ligtenberg M, Goossens M, Punt C . EMAST is associated with a poor prognosis in microsatellite instable metastatic colorectal cancer. PLoS One. 2015; 10(4):e0124538. PMC: 4401564. DOI: 10.1371/journal.pone.0124538. View

18.

Arai H, Okudela K, Oshiro H, Komitsu N, Mitsui H, Nishii T . Elevated microsatellite alterations at selected tetra-nucleotide (EMAST) in non-small cell lung cancers--a potential determinant of susceptibility to multiple malignancies. Int J Clin Exp Pathol. 2013; 6(3):395-410. PMC: 3563186. View

19.

. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517):202-9. PMC: 4170219. DOI: 10.1038/nature13480. View

20.

Chen M, Chang S, Lin P, Yang S, Lin C, Lan Y . Combined Microsatellite Instability and Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) Might Be a More Promising Immune Biomarker in Colorectal Cancer. Oncologist. 2019; 24(12):1534-1542. PMC: 6975953. DOI: 10.1634/theoncologist.2019-0171. View